Actively Recruiting
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
Led by M.D. Anderson Cancer Center · Updated on 2026-03-11
50
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are observing adults who have been treated with radiofrequency ablation (RFA) for benign or indeterminate thyroid nodules and low-risk papillary thyroid cancers. The study aims to track changes in thyroid nodule size over time, assess the long-term effectiveness of RFA, and understand the quality of life of patients after this treatment. It also monitors ultrasound features of thyroid nodules and any adverse events related to the procedure. Participants in this observational study undergo ultrasound-guided RFA as part of their clinical care. Researchers collect data about their health and quality of life using questionnaires that ask about symptoms and complaints related to their thyroid condition. The study focuses on patients who have benign nodules causing symptoms, indeterminate nodules, papillary thyroid carcinoma without metastasis, or locally recurrent thyroid cancer smaller than 2 cm. During the study, participants complete health-related quality of life questionnaires over an average of one year. Medical appointments include evaluations of thyroid nodule volume and ultrasound imaging to observe changes after RFA. The study monitors adverse events and gathers detailed patient-reported outcomes, helping to understand the long-term impact and safety of RFA treatment. Participation involves regular assessments until study completion, which may continue through the end of 2030.
CONDITIONS
Brief Title
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Scheduled for ultrasound-guided radiofrequency ablation (RFA) for benign thyroid nodules, indeterminate thyroid nodules, low-risk differentiated thyroid cancer (DTC), or recurrent papillary thyroid cancer (PTC)
- Age 18 years or older
- Not a surgical candidate or has declined surgery
- Able and willing to provide written informed consent
- Diagnosis of biopsy-proven benign thyroid nodules causing symptoms, biopsy-proven indeterminate nodules (AUS or follicular neoplasm), papillary thyroid carcinoma without metastasis, or locally recurrent thyroid cancer smaller than 2 cm
You will not qualify if you...
- Considered unsuitable for RFA by the treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants who undergo routine care with ultrasound-guided radiofrequency ablation (RFA) for thyroid nodules are observed over time to evaluate changes in nodule volume, sonographic features, quality of life, and adverse events.
Periodic visits aligned with clinical care for assessments and questionnaires
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
V
Victoria E Banuchi, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here